Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06973291 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Takeda.
- Active
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
- 20
- Study locations
NCT06973291: Active Phase 3 study of Plaque Psoriasis, sponsored by Takeda.
NCT06973291 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Takeda. The registered enrollment target is 606 participants, above the 402-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06973291, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.
Primary Outcome
PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72 (less than or equal to \[\<=\] 3 representing mild disease, greater than or equal to \[\>=3\] to 15 representing moderate disease, and \>=15 indicating severe disea
Conditions Studied
Interventions
- DRUG Deucravacitinib
- DRUG Zasocitinib
- DRUG Placebo to match zasocitinib
- DRUG Placebo to match deucravacitinib
Study Locations (20)
California
- Zenith Research, Inc. - Beverly Hills
- First OC Dermatology Research Inc. - Fountain Valley
- UNISON Clinical Trials (Shahram Jacobs md inc.) - Sherman Oaks
Florida
- Direct Helpers Research Center - Hialeah
- San Marcus Research Clinic Inc - Miami Lakes
- Advanced Clinical Research Institute - Tampa
Arkansas
- Johnson Dermatology - Fort Smith
- Burke Pharmaceutical Research - Hot Springs
Connecticut
- Central Connecticut Dermatology, PLLC - Cromwell
- Yale University School of Medicine - New Haven
Illinois
- Arlington Dermatology - Rolling Meadows
- Endeavor Health Clinical Trials - Skokie
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Maryland
- Lawrence J Green, MD LLC - Rockville
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2026-07-03 |
| Phase | Phase 3 |
What the registry record for NCT06973291 still lists
NCT06973291 is an interventional study that assigns participants to a tested intervention. The registered 606 participants enrollment target is mid-sized for trials with a published cap, above the 402-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (51% higher).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Deucravacitinib is the first listed.
NCT06973291 names 20 study sites across 13 states, led by California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06973291 about?
NCT06973291 is a clinical study titled "A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis". The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsula...
What is the current status of trial NCT06973291?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2025-07-09. Estimated completion is 2026-07-03.
What conditions does trial NCT06973291 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06973291?
The interventions under investigation include: Deucravacitinib (DRUG), Zasocitinib (DRUG), Placebo to match zasocitinib (DRUG), Placebo to match deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT06973291?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06973291 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06973291's enrollment target sits among peer trials
606 12th of 45 higher than 34 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI